Patent application number | Description | Published |
20080300304 | Ginger Fraction For Inhibiting Human Cyp Enzymes - The present invention relates to a process for preparing a ginger fraction, the fraction prepared by this process and the use thereof on its own or combined with drugs for inhibiting human cytochrome P450 (CYP) enzymes (particularly cytochrome P450 3A4, CYP3A4) for positively influencing the oral bioavailability and pharmacokinetics of active substances. | 12-04-2008 |
20090130197 | EXTENDED RELEASE PELLET FORMULATION CONTAINING PRAMIPEXOLE OR A PHARMACEUTICALLY ACCEPTABLE SALT - An extended release pellet comprising an active ingredient selected from pramipexole and the pharmaceutically acceptable salts thereof, and at least one release-modifying excipient. | 05-21-2009 |
20090308960 | DEVICE FOR GRANULATING AND/OR MIXING - A device for granulating and/or mixing, in particular for a pharmaceutical active agent formulation, comprising a cylindrical granulation chamber ( | 12-17-2009 |
20100044398 | DOSING DEVICE, IN PARTICULAR DOSING DEVICE FOR MEDICAMENTS, AND THE USE OF SAID DOSING DEVICE - The invention relates to a dosing device for dosing small-particulate pharmaceutical preparations with at least one chamber for receiving a larger amount of the preparation and a dosing unit, comprising a rotary valve carrying at least one dosing chamber for receiving a defined partial amount (defined dose) of the preparation, whereby the dosing chamber is moveable between a filling position, in which it is to be filled with a preparation from the chamber, and a dispensing position, in which the preparation is to be dispensed from the dosing chamber. The rotary valve is rotable about a substantially horizontal axis, and assigned an adjustment device for setting the volume in the dosing chamber and a twisting device, whereby the twisting device constitutes the actuator for the adjustment device. The plastic material chosen such, that no softening agents or other volatile components will be released, in order to prevent drug contamination. | 02-25-2010 |
20110045090 | FORMULATIONS OF FLIBANSERIN - The present invention provides pharmaceutical release systems comprising an therapeutically effective amount of flibanserin. | 02-24-2011 |
20120122887 | SOLID STATE FORMS OF A POTENT HCV INHIBITOR - This invention relates to novel sodium salt forms of the following Compound (1), and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection: | 05-17-2012 |
20130209519 | FORMULATIONS OF FLIBANSERIN - The present invention provides pharmaceutical release systems comprising an therapeutically effective amount of flibanserin. | 08-15-2013 |
20140057928 | SOLID STATE FORMS OF A POTENT HCV INHIBITOR - This invention relates to novel sodium salt forms of the following Compound (1), and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection: | 02-27-2014 |
20140094523 | SOLID AMBROXOL-CONTAINING PREPARATION - The present invention relates to solid preparations containing ambroxol which are obtainable by melt extrusion of the mixture consisting of a) 30 to 80% by weight of ambroxol hydrochloride, b) 2 to 68% by weight of at least one hydrogenated vegetable oil, c) 2 to 68% by weight of at least one mixture containing fatty acid ester and/or hydroxy fatty acid ester and d) 0 to 66% by weight of one or more pharmaceutical adjuvants, based in each case on the total amount of the preparation and its use for secretolytic treatment in acute and chronic bronchopulmonary diseases. | 04-03-2014 |